Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$24.2MCash on Hand
7mo Cash Runway
Follow PTHS by emailGet an email when PTHS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PTHS, unsubscribe in one click. Privacy
📣 What PTHS Says Is Next
first quarter of 2027 · “The transaction remains on track to close by the end of the first quarter of 2027, subject to customary closing conditions including approval by Castle Creek’s stockholders.”
Company press release, Nov 12, 2026 · SEC filing
first quarter of 2027 · “The transaction has been approved by the boards of directors of both companies and is expected to close by the end of the first quarter of 2027, subject to customary closing conditions including approval by Castle Creek’s stockholders.”
Company press release, Oct 30, 2026 · SEC filing
Early 2027 · “Anticipated Commercial Launch: Early 2027 Pelthos Opportunity Acquired from BioFrontera in October 2025 FDA Approved in 2017 Exclusivity until 2032 1https://www.cdc.gov/group-a-strep/about/impetigo.html Xeglyze: New Product Acquisition 19 Xeglyze (abametapir) Lotion for the Treatment of Head Lice Sources: CDC Website, Xeglyze Pack Insert, FDA.gov”
Company press release, May 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Reported Q3 2026 Zelsuvmi net product revenue of $15.2 million, up 114% year over year and down 1% sequentially, with 12,384 units dispensed. Announced a merger with Castle Creek expected to close by end of Q1 2027, and a $10.0 million additional borrowing from Horizon. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 30, 2026 ·
Deal Pelthos agreed to merge with Castle Creek Biosciences in a two-step deal. Castle Creek holders get 5,200,000 Pelthos shares at closing, plus contingent shares, up to $300 million in milestones and a share of any priority review voucher tied to D-Fi. Closing is expected by end of Q1 2027. Form 8-K · SEC filing · Press release
Oct 1, 2026 ·
Shareholder vote Stockholders elected eight directors, ratified Grant Thornton LLP as auditor for 2026, and approved the 2026 Equity Incentive Plan, which replaces the 2023 plan. Votes were held September 29, 2026 with 70.0% of voting power present. Form 8-K · SEC filing
Aug 18, 2026 ·
Shareholder vote Pelthos will hold its 2026 virtual annual meeting on September 29, 2026. Shareholders will vote on electing eight directors, ratifying Grant Thornton LLP as auditor for 2026, and approving the 2026 Equity Incentive Plan. The Board recommends voting FOR all three. Form DEF 14A · SEC filing
Aug 13, 2026 ·
Pelthos said its audit committee concluded on August 12, 2026 that its Q1 2026 financial statements should no longer be relied upon due to a misapplication of ASC 820 on convertible debt valuation. Form 8-K · SEC filing
Aug 13, 2026 ·
Amended quarterly report for the period ended Mar 31, 2026 Form 10-Q/A · SEC filing
Aug 13, 2026 ·
Earnings Q2 2026 Zelsuvmi net product revenue rose 45% to $15.4 million from $10.7 million in Q1, with 11,925 units dispensed. The filing also discloses restatement of Q1 2026 financial statements, which should no longer be relied upon. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
PTHS holds $24.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.4M/quarter from operations,
an estimated runway of 7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:44 · Elevated
Cash runway 7 months +30
Shelf registration (S-3, Feb 2026) +10
Share count +28% in a year +14
Raised after last reported balance sheet (Oct 2026) -10
Share count 3,930,709 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PTHS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PTHS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.